Effect of sunitinib combined with ionizing radiation onendothelial cells

Journal of Radiation Research

Volumn 52, Issue 1, 2011, Pages 1-8

  Zhang, Hai Ping ^a,b   Takayama, Koichi ^c   Su, Bo ^b   Jiao, Xiao dong ^a   Li, Rui ^a   Wang, Jie Jun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Akt; Caspase 3; Endothelial cell; Ionizing radiation; PI3K; Sunitinib

Indexed keywords

CELL DEATH; CYTOTOXICITY; ENDOTHELIAL CELLS; RADIATION SHIELDING;

AKT; CASPASE-3; CELL CYCLE; COMBINATION THERAPY; ENDOTHELIAL-CELLS; IN-VITRO; MICRO-VASCULATURE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL PATHWAYS; SUNITINIB;

IONIZING RADIATION;

EID: 79751517521     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.10013     Document Type: Article

References (28)

1. Ringborg U, et al (2003) The swedish council on technology assessment in health care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions. Acta Oncol 42(5-6): 357-365.
2. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58-62.
3. Li WW (2000) Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 7(10): 800-811.
4. Seghezzi G, et al (1998) Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 141(7): 1659-1673.
5. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 (Suppl 1): 3-10.
6. Giavazzi R, et al (2001) Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 61(1): 309-317.
7. Rosenkranz S and Kazlauskas A (1999) Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 16(3): 201-216.
8. Sato N, et al (1993) Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 142(4): 1119-1130.
9. Gorski DH, et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59(14): 3374-3378.
10. Geng L, et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61(6): 2413-2419.
11. Garcia-Barros M, et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622): 1155-1159.
12. Colquhoun AJ, et al (2007) Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. J Radiat Res (Tokyo) 48(5): 351-360.
13. Chinnaiyan P, et al (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8): 3328-3335.
14. Kozin SV, et al (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61(1): 39-44.
15. Geng L, et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61(6): 2413-2419.
16. Hess C, et al (2001) Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85(12): 2010-2016.
17. Griffin RJ, et al (2002) Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62(6): 1702-1706.
18. Schueneman AJ, et al (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63(14): 4009-4016.
19. Mendel DB, et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1): 327-337.
20. Tan J and Hallahan DE (2003) Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res (22): 7663-7667.
21. Pawlik TM and Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59(4): 928-942.
22. Ning S and Knox SJ (1999) G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat Res 151(6): 659-669.
23. Edwards E, et al (2002) Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62(16): 4671-4677.
24. Zingg D, et al (2004) Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 64(15): 5398-5406.
25. Liu Y (1999) Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms. Am J Physiol 277: F624-F633.
26. Toulany M, et al (2006) Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increasesradiosensitivity of K-Ras mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12(13): 4119-4126.
27. Kim W, et al (2007) Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma. J Radiat Res (Tokyo) 48(3): 187-195.
28. Kao J, et al (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115(15): 3571-3580.